The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
What effect does idasanutlin have on TP53-mutated clones in patients with polycythemia vera?
Featured:
Jean-Jacques KiladjianThe MPN Hub were pleased to speak to Jean-Jacques Kiladjian, University of Paris, Paris, FR, during the 61st American Society of Hematology (ASH) meeting in Orlando, US. We asked: What effect does idasanutlin have on TP53-mutated clones in patients with polycythemia vera?
Jean-Jacques Kiladjian discusses the MDM2 inhibitor, idasanutlin, which can potentially reactivate the TP53 pathway in patients who don't have TP53 mutation. He talks about an observation in a study that saw idasanutlin treatment to result in the expansion of TP53-mutated clones, and when idasanutlin treatment was halted, these clones spontaneously diminished. Jean-Jacques Kiladjian explains, therefore, a careful selection of patients that are offered MDM2 inhibitors are needed.
What effect does idasanutlin have on TP53-mutated clones in patients with polycythemia vera?
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?